Research Article
Shenmayizhi Formula Combined with Ginkgo Extract Tablets for the Treatment of Vascular Dementia: A Randomized, Double-Blind, Controlled Trial
Table 4
Comparison of ET-1, NO, VEGF, and vWF before and after treatment.
| | SMYZF group (n = 85), median (IQR) | Ginkgo group (n = 87), median (IQR) | value |
| ET-1 (pg/mL) | | | | Before treatment | 48.73 (24.86–96.48) | 56.20 (31.22–146.48) | 0.271 | After treatment | 22.04 (8.79–61.19) | 30.85 (17.63–67.73) | 0.043 | NO (μmol/L) | | | | Before treatment | 16.06 (9.72–25.40) | 15.14 (8.94–24.01) | 0.614 | After treatment | 20.30 (11.26–36.82) | 15.65 (9.04–26.86) | 0.040 | VEGF (pg/mL) | | | | Before treatment | 128.37 (76.14–216.21) | 130.99 (56.13–189.34) | 0.207 | After treatment | 301.47 (187.20–447.45) | 308.16 (196.57–477.22) | 0.491 | vWF (ng/mL) | | | | Before treatment | 11643.45 (6466.81–15808.98) | 9676.81 (6391.48–14450.25) | 0.193 | After treatment | 9722.73 (6176.22–14078.82) | 8913.02 (6278.56–13478.81) | 0.385 |
|
|
Significant effect ( <0.05). |